319 related articles for article (PubMed ID: 26991422)
1. Androgen receptor-related diseases: what do we know?
Shukla GC; Plaga AR; Shankar E; Gupta S
Andrology; 2016 May; 4(3):366-81. PubMed ID: 26991422
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor modulation: lessons learned from beyond the prostate.
Sharifi N; Figg WD
Cancer Biol Ther; 2007 Sep; 6(9):1358-9. PubMed ID: 17881894
[TBL] [Abstract][Full Text] [Related]
3. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
Chatterjee B
Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in androgen receptor action.
Lee HJ; Chang C
Cell Mol Life Sci; 2003 Aug; 60(8):1613-22. PubMed ID: 14504652
[TBL] [Abstract][Full Text] [Related]
5. Progesterone receptor in the prostate: A potential suppressor for benign prostatic hyperplasia and prostate cancer.
Chen R; Yu Y; Dong X
J Steroid Biochem Mol Biol; 2017 Feb; 166():91-96. PubMed ID: 27125450
[TBL] [Abstract][Full Text] [Related]
6. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.
Comuzzi B; Lambrinidis L; Rogatsch H; Godoy-Tundidor S; Knezevic N; Krhen I; Marekovic Z; Bartsch G; Klocker H; Hobisch A; Culig Z
Am J Pathol; 2003 Jan; 162(1):233-41. PubMed ID: 12507906
[TBL] [Abstract][Full Text] [Related]
7. Role of the androgen receptor CAG repeat polymorphism in prostate cancer, and spinal and bulbar muscular atrophy.
Kumar R; Atamna H; Zakharov MN; Bhasin S; Khan SH; Jasuja R
Life Sci; 2011 Mar; 88(13-14):565-71. PubMed ID: 21284948
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function.
Li W; Cavasotto CN; Cardozo T; Ha S; Dang T; Taneja SS; Logan SK; Garabedian MJ
Mol Endocrinol; 2005 Sep; 19(9):2273-82. PubMed ID: 15919721
[TBL] [Abstract][Full Text] [Related]
9. The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs.
Mukherjee S; Cruz-Rodríguez O; Bolton E; Iñiguez-Lluhí JA
J Biol Chem; 2012 Sep; 287(37):31195-206. PubMed ID: 22829593
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of androgen action--a historical perspective.
Brinkmann AO
Methods Mol Biol; 2011; 776():3-24. PubMed ID: 21796517
[TBL] [Abstract][Full Text] [Related]
11. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer.
Bauman DR; Steckelbroeck S; Peehl DM; Penning TM
Endocrinology; 2006 Dec; 147(12):5806-16. PubMed ID: 16959841
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular aspects of androgen receptor defects.
Wieacker PF; Knoke I; Jakubiczka S
Exp Clin Endocrinol Diabetes; 1998; 106(6):446-53. PubMed ID: 10079022
[TBL] [Abstract][Full Text] [Related]
13. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
14. The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer.
Avila DM; Zoppi S; McPhaul MJ
J Steroid Biochem Mol Biol; 2001; 76(1-5):135-42. PubMed ID: 11384871
[TBL] [Abstract][Full Text] [Related]
15. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
16. Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer.
Wen S; Chang HC; Tian J; Shang Z; Niu Y; Chang C
Am J Pathol; 2015 Feb; 185(2):293-301. PubMed ID: 25432062
[TBL] [Abstract][Full Text] [Related]
17. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.
Leach DA; Need EF; Toivanen R; Trotta AP; Palethorpe HM; Tamblyn DJ; Kopsaftis T; England GM; Smith E; Drew PA; Pinnock CB; Lee P; Holst J; Risbridger GP; Chopra S; DeFranco DB; Taylor RA; Buchanan G
Oncotarget; 2015 Jun; 6(18):16135-50. PubMed ID: 25965833
[TBL] [Abstract][Full Text] [Related]
18. Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer.
Liu X; Han W; Gulla S; Simon NI; Gao Y; Liu J; Wang L; Yang H; Zhang X; Chen S
Prostate; 2016 May; 76(7):649-61. PubMed ID: 26847655
[TBL] [Abstract][Full Text] [Related]
19. [Some clinically relevant findings in recent research on androgens].
Tamm J; Voigt KD
Schweiz Med Wochenschr; 1971 Jul; 101(30):1078-83. PubMed ID: 4110881
[No Abstract] [Full Text] [Related]
20. The biological and clinical advances of androgen receptor function in age-related diseases and cancer [Review].
Takayama KI
Endocr J; 2017 Oct; 64(10):933-946. PubMed ID: 28824023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
